Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution.
BACKGROUND
To evaluate if peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo.


METHODS
Male Wistar rats were dialyzed three times daily for 28 days with 1.36% Dianeal (two groups: with (D+R) or without (D) rosiglitazone) or 1.36% Physioneal (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls.


RESULTS
Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway.


CONCLUSIONS
The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.
Yao
Qiang
Q
Divisions of Baxter Novum and Renal Medicine, Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden.
Pawlaczyk
Krzysztof
K
Ayala
Ernesto Rodríguez
ER
Kuzlan
Malgorzata
M
Styszynski
Arkadiusz
A
Breborowicz
Andrzej
A
Heimburger
Olof
O
Qian
Jiaqi
J
Stenvinkel
Peter
P
Axelsson
Jonas
J
Lindholm
Bengt
B
D000818:Animals; D015312:Hemodialysis Solutions / Q000009:adverse effects* / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D047495:PPAR gamma / Q000037:antagonists & inhibitors*; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010537:Peritoneum / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D015398:Signal Transduction / Q000187:drug effects; D051785:Smad Proteins / Q000378:metabolism; D045162:Thiazolidinediones / Q000494:pharmacology*; D015291:Transforming Growth Factors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D015312:Hemodialysis Solutions; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D051785:Smad Proteins; D045162:Thiazolidinediones; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D000077154:Rosiglitazone; D015291:Transforming Growth Factors